Ranbaxy recalls generic Lipitor in US; launches anti-acne drug

Hannah Blake

pharmaphorum

Ranbaxy Laboratories Ltd has temporary recalled atorvastatin, its generic version of Pfizer’s cholesterol-lowering drug Lipitor, in the United States after certain batches were found to contain glass particles.

The Indian pharmaceutical company is conducting an investigation, which is expected to take two weeks, but did not disclose further information. Analysts believe the recall could cause shortages of the drug in the US.

In other Ranbaxy news, the company today launched its anti-acne drug, absorica (isotretinoin) capsules. Absorica is indicated for the treatment of severe recalcitrant nodular acne in patients 12 years of age and older.

“We are most pleased to make Absorica available as a valuable option for dermatologists and a subset of patients who suffer from severe recalcitrant nodular acne. Absorica will be the flagship brand of the Ranbaxy dermatology product portfolio in the U.S.”

Senior Director, Ranbaxy Laboratories Inc. Dr. Ashish Anvekar.

&nbsp,

pharma-PPM-toolbox-5-6-March-2013

&nbsp,

Related news:

Ranbaxy recalls generic Lipitor in United States (Reuters)

Ranbaxy launches anti-acne drug in the US market (The Indian Express)

Reference links:

Ranbaxy official press release

&nbsp,

Don't miss your daily pharmaphorum news.
SUBSCRIBE free here.